Now showing items 1-4 of 4
A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia
Background: While the atypical antipsychotics should ultimately reduce the prevalence of tardive dyskinesia, it is likely to remain a significant clinical problem for a long time to come. No strategy has clearly emerged ...
Remission in first-episode psychosis: Predictor variables and symptom improvement patterns
Background: Previous attempts to identify clinically useful predictors of treatment outcome in schizophrenia have been hampered by methodological inconsistencies, including a lack of standardized outcome measures. Recently ...
The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial
Objective: Worldwide, conventional antipsychotic medication continues to be used extensively, and tardive dyskinesia (TD) remains a serious complication. The primary objective of the present study was to compare the efficacy ...
Neurological abnormalities in first-episode schizophrenia: Temporal stability and clinical and outcome correlates
Objective: Neurological abnormalities in subjects with schizophrenia have been regarded as diagnostically non-specific and non-localising. This study assessed the temporal stability of neurological abnormalities in subjects ...